tenacio, a company focused on digitising cardiovascular care to improve patient outcomes and reduce healthcare costs, has announced its OptiCor patient management platform is now commercially available following a completed review by the US Food and Drug Administration (FDA).
At the centre of the platform’s development, the researchers emphasise the prevalence of atrial fibrillation (AF) as the most common heart rhythm disorder, affecting one out of three individuals during their lifetime. Resulting in strokes, hospitalisations, and premature death, the authors refer to registries showing 40% of these patients are not optimally treated.
OptiCor is a patient management platform to address this unmet need through clinically meaningful prediction of events such that patients and providers can make more informed collective decisions about disease management. It has demonstrated its potential for significant reductions in outcome events in a 52,000 patient in-silico study.
“Still today, many patients with atrial fibrillation are not treated optimally and therefore suffer unnecessarily from strokes and premature deaths. Tools which support physicians in treating their patients according to guidelines are urgently needed,” says Christopher Granger (Duke University, North Carolina, USA).
“The launch of OptiCor in the US following an FDA review marks an important milestone for tenacio. Using OptiCor is expected to result in better outcomes for cardiovascular patients.” says Georg van Husen, CEO of tenacio.
OptiCor is a digital decision support tool with a proprietary risk prediction algorithm combined with curated clinical evidence and guideline-based patient treatment recommendations. It has been designated by the FDA as a clinical decision support software.
